Sinovac Biotech Ltd, a biopharmaceutical product provider in China, officially unveiled a vaccine quality research center in Changping district of Beijing on Sunday. With a total investment of 500 million yuan ($74 million), the construction of the center has been included both in the key construction projects of Beijing in 2022 and the key medical and health projects in Changping district in 2022. The facility, which is expected to start operations in the fourth quarter of 2023, will be mainly used for the whole-process quality research of vaccines---from raw materials to finished products. Up to date, Sinovac has supplied vaccines

Sinovac Biotech Ltd, a biopharmaceutical product provider in China, announced on Tuesday that a phase-3 clinical trial for its inactivated quadrivalent influenza vaccine was initiated in the Republic of Chile. The clinical trial aims to evaluate the immunogenicity and safety of the quadrivalent influenza vaccine among individuals aged 3-year-old and above. In total, 1,600 volunteers will be recruited. Half of them will receive one or two doses of the Sinovac vaccine, while the other half will receive a different quadrivalent influenza vaccine commercially available in Chile. All of the participants will be observed for 28 days following the completed inoculation

Chinese vaccine producer Sinovac Biotech officially kicked off a clinical trial in Hong Kong on Monday to assess the safety and immunogenicity of its Omicron-specific COVID-19 inactivated vaccine which will be used as a booster shot in healthy adults. The trial program plans to recruit around 300 or more healthy volunteers who are above the age of 18 and who have already been inoculated with two or three shots of either inactivated or mRNA COVID-19 vaccine. This study is being led by a research team from the University of Hong Kong Clinical Trials Centre in collaboration with Gleneagles Hospital Hong